Hillstream BioPharma, Inc.
HILS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | -0.00 | -0.28 |
| FCF Yield | -4,646.49% | -3,089.55% | -149.70% | -3.03% |
| EV / EBITDA | 0.27 | 1.13 | 0.31 | -27.62 |
| Quality | ||||
| ROIC | -950.86% | -103.55% | -124.14% | 175.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.78 | 0.77 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -49.34% | -11.32% | -503.73% | -0.72% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | 1.16 | 0.95 | -1.57 |
| Interest Coverage | 908.64 | 572.87 | -4.32 | -3.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |